Rigaku Announces New Handheld Raman Analyzer

Article

Rigaku Raman Technologies will showcase customizable handheld Raman analyzer for accurate and comprehensive raw material ID at CPhI 2014.

Rigaku Raman Technologies, creator of handheld and portable Raman spectrometers, will showcase its newest handheld Raman analyzer for raw material identification (RMID) in booth 1C82 at CPhI Worldwide 2014.

Progeny delivers improved performance, ease of use, and confidence to ensure an accurate and comprehensive range of material identification in a handheld form.

Pharmaceutical manufacturing companies are under increasing pressure to reduce the costs and time associated with raw material ID while complying with regulatory requirements. Progeny is a handheld Raman analyzer designed to be customizable for seamless integration into existing workflows. Progeny eliminates issues of fluorescence interference with the use of a 1064nm excitation laser. This unique feature enables users of handheld Raman to measure materials through thick, colored bottles, such as polysorbate 20 and polysorbate 80. Other materials that are known to cause fluorescence interference, such as sodium carboxy methoycellulose, alginic acid, and cell culture media typically used in biopharmaceuticals, are now detectable with Progeny.

Reducing the costs associated with RMID is an important consideration for pharmaceutical manufacturing companies. In addition, Progeny’s ergonomic allows measurements to be taken directly from warehouse drums within a matter of seconds, reducing the risk of cross-contamination. The analyzer also has a user-friendly angled display, touchscreen interface for easy implementation into a customized workflow. Error free data entry tracking is also now achievable with Progeny’s integrated digital camera and a 21 CFR Part 11 compliant electronic signature. The device also features an adjustable focusing nose cone to provide readings through thicker packaging materials such as polymer or glass.

Source: Rigaku

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content